This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
===== India, Russia and CIS countries ===== Valparin Chrono by Sanofi India Valprol CR by Intas Pharmaceutical (India) Encorate Chrono by Sun Pharmaceutical (India) Serven Chrono by Leeven APL Biotech (India)
By July 2019, this has not happened, according to The Record. Critics raised concerns that Hydro One will not experience stability as Premier Ford's government has a "record of reaching in to exert control." On March 21, 2019, Minister Rickford tabled Bill 87, the Fixing the Hydro Mess Act, which was given royal assent on May 9. Bill 87 overhauled the Ontario Energy Board and eliminated the Liberal's 2017 Fair Hydro Plan which the PC's said would save $442 million. The Liberal Plan "subsidized electricity with borrowed money" in response to a "public outcry over soaring hydro rates, particularly in rural areas." The Liberals created the Ontario Power Generation Inc (OPG Trust) as the Financial Services Manager to manage the debt. Bonnie Lysyk, the Auditor General, released a special report on October 17, 2017, which said the "structure of the plan" was in violation of the provincial government's accounting rules. She said that the Plan, which committed the government to discount consumer electricity rates for ten years, would cost the province "$21 billion in interest over the next 30 years." The 2017 AG report said that it would cost $4 billion more on the $18.4 billion loan to use the Ontario Power Generation (OPG Trust) than if the province took out the loan because the province would have a lower interest rate than the OPG Trust. The Ford government said that they would maintain [the] 25 per cent time-of-use rates, that was part of the Liberal's Fair Hydro Plan.
The Health Care Financing Administration (HCFA) was a proponent of the exam noting that it should "significantly increase the pool of personnel qualified for technologist positions in independent labs." Following the exam's discontinuation in 1987, in 1992 HCFA urged the reinstatement of the exam to address the shortage of properly credentialed laboratory personnel. American Association of Bioanalysts (AAB) and the International Society for Clinical Laboratory Technology (ISCLT) supported its reinstatement, while ASCP opposed it. Those who passed the exam were given the designatory letters: CLT (HEW) and later CLT (HHS) for Clinical Laboratory Technologist. HEW certified techs were paid less than the degree-bearing MT ASCP certified techs for the same work. Results of the HEW/HHS exam can be obtained via the HHS System of Records Notices (SORNs) SORN 09–20–0157.
=== Detection in body fluids === Acetylfentanyl may be quantitated in blood, plasma, or urine by liquid chromatography-mass spectrometry to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation. Postmortem peripheral blood acetylfentanyl concentrations have been in a range of 89–945 μg/L in victims of acute overdosage.
Biomimetics is a field that aims to produce materials and systems that replicate those present in nature. In the context of tissue engineering, this is a common approach used by engineers to create materials for these applications that are comparable to native tissues in terms of their structure, properties, and biocompatibility. Material properties are largely dependent on physical, structural, and chemical characteristics of that material. Subsequently, a biomimetic approach to system design will become significant in material integration, and a sufficient understanding of biological processes and interactions will be necessary. Replication of biological systems and processes may also be used in the synthesis of bio-inspired materials to achieve conditions that produce the desired biological material. Therefore, if a material is synthesized having the same characteristics of biological tissues both structurally and chemically, then ideally the synthesized material will have similar properties. This technique has an extensive history originating from the idea of using natural phenomenon as design inspiration for solutions to human problems. Many modern advancements in technology have been inspired by nature and natural systems, including aircraft, automobiles, architecture, and even industrial systems. Advancements in nanotechnology initiated the application of this technique to micro- and nano-scale problems, including tissue engineering.
Sources: en.wikipedia.org
A concentrated coffee/milk/sugar mixture was produced for the Union army during the American Civil War under the name Essence of Coffee, a teaspoonful of which was mixed with a cup of hot water. It had the consistency of axle grease, and proved so unpopular with the troops that it was soon discontinued. The brand Camp Coffee, a liquid coffee and chicory essence, was first produced in 1876 by Paterson & Sons Ltd in Scotland. The invention for powdered soluble instant coffee was filed on 28 January 1889 and patented in 1890, by David Strang of Invercargill, New Zealand, under patent number 3518, and sold as "Strang's Soluble Coffee Powder", citing the patented "Dry Hot-Air" process. Some modern sources have credited French humorist and writer Alphonse Allais with the invention. The invention had previously been attributed to Satori Kato, a Japanese scientist working in Chicago in 1901. Kato introduced the powdered substance in Buffalo, New York, at the Pan-American Exposition. George Constant Louis Washington developed his own instant coffee process shortly thereafter, and first marketed it commercially (1910). The product was expensive in relation to its quality however, and had the disadvantage of being highly hygroscopic. In the 1938 Nestlé produced a more stable, free-flowing instant coffee powder under the Nescafé brand. It had previously not been possible to spray dry coffee extract due to its high levels of low molecular weight sugars and acids. These cause the spray dried powder to become sticky and clump into a paste.
On 18 July 1966, the ICJ ruled that it had no authority to decide on the South West African affair. Furthermore, the court found that while Ethiopia and Liberia had locus standi to institute proceedings on the matter, neither had enough vested legal interest in South West Africa to entitle them to a judgement of merits. This ruling was met with great indignation by SWAPO and the OAU. SWAPO officials immediately issued a statement from Dar es Salaam declaring that they now had "no alternative but to rise in arms" and "cross rivers of blood" in their march towards freedom. Upon receiving the news, SWALA escalated its insurgency. Its third group, which had infiltrated Ovamboland in July, attacked white-owned farms, traditional Ovambo leaders perceived as South African agents, and a border post. The guerrillas set up camp at Omugulugwombashe, one of five potential bases identified by SWALA's initial reconnaissance team as appropriate sites to train future recruits. Here, they drilled up to thirty local volunteers between September 1965 and August 1966. South African intelligence became aware of the camp by mid 1966 and identified its general location. On 26 August 1966, the first major clash of the conflict took place when South African paratroops and paramilitary police units executed Operation Blouwildebees to capture or kill the insurgents. SWALA had dug trenches around Omugulugwombashe for defensive purposes, but was taken by surprise and most of the insurgents quickly overpowered. SWALA suffered 2 dead, 1 wounded, and 8 captured; the South Africans suffered no casualties.
=== Triphasic bonds === Other type of "dynamic bonds" have been defined in addition to the original types of catch bonds, slip bonds and ideal bonds classified by Dembo. Unlike slip bonds, which have been observed in the entire force range tested, catch bonds only exist within certain force range as any molecular bond would eventually be overpowered by high enough force. Therefore, catch bonds are always followed by slip bonds, hence termed "catch-slip bonds". More variations have also been observed, e.g., triphasic slip-catch-slip bonds.
=== Pet food === In the US, Turkestan cockroaches are sometimes kept to feed to pet reptiles and other insectivores, chosen partly because they can't climb smooth surfaces and don't burrow. Cockroaches have been replacing crickets, the most popular feeder insect for decades, due to the cricket's noise, odor, short lifespan, and expense. Turkestan cockroaches are a popular choice of species, and are readily available for sale over the Internet, which may hasten their spread to new habitats. Although reliable information on specific dietary requirements of insectivores is scant, Turkestan cockroaches provide a high-protein, low fat nutrition composition similar to crickets, more so than mealworms or superworm larvae provide. The gut contents of the cockroach, depending on its diet, may provide essential nutrients unavailable from a cockroach with an empty gut. In a study of commercially ordered specimens, small second instar nymphs (0.9–1.3 cm or 0.35–0.51 in) consisted of 21% dry matter, made of 76% crude protein and 14% crude fat, while medium third instar nymphs (1.3-1.9 cm) consisted of 28% dry matter, made of 53% crude protein and 27% crude fat. Mineral content is well represented except for a low calcium:phosphorus ratio typical in cockroaches, and calcium supplementation may be advisable. Vitamin A and E content was relatively low, and is generally significantly higher in free-ranging cockroaches.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.